

PatientID: HIVDR-824-23

Sebuttemba 27, 2023

Color Code

■ HR: High-Level Resistance ■ PLR: Potential Low-Level Resistance
■ LR: Low-Level Resistance ■ IR: Intermediate Resistance
■ S: Susceptible

| DRUG.CLASS | DRUG | RESISTANCE.PROFILE | DRMS.above.20.percent.prevalence |
|------------|------|--------------------|----------------------------------|
| PI | ATV | S | |
| | DRV | S | |
| | FPV | S | |
| | IDV | S | |
| | LPV | S | |
| | NFV | S | |
| | SQV | S | |
| | TPV | S | |
| NRTI | ABC | LR | M184MV |
| | AZT | S | |
| | D4T | S | |
| | DDI | PLR | |
| | FTC | HR | |
| | LMV | HR | |
| | TDF | S | |
| NNRTI | DOR | S | |
| | EFV | S | |
| | ETR | S | |
| | NVP | S | |
| | RPV | S | |
| INSTI | BIC | S | |
| | CAB | S | |
| | DTG | S | |
| | EVG | S | |
| | RAL | S | |

Appendix

Drug abbreviations in full

| DRUG.CLASS | ABBREVIATION | DRUG.NAME |
|--------------|--------------|----------------|
| PI | ATV | Atazanavir |
| | DRV | Darunavir |
| | FPV | Fosamprenavir |
| | IDV | Indinavir |
| | LPV | Lopinavir |
| | NFV | Nelfinavir |
| | SQV | Saquinavir |
| | TPV | Tipranavir |
| NRTI | ABC | Abacavir |
| | AZT | Azidothymidine |
| | DFT | Stavudine |
| | DDI | Didanosine |
| | FTC | Emtricitabine |
| | LMV | Lamivudine |
| | TDF | Tenofovir |
| NNRTI | DOR | Doravirine |
| | EFV | Efavirenz |
| | ETR | Etravirine |
| | NVP | Nevirapine |
| | RPV | Rilpivirine |
| INSTI | BIC | Bictegravir |
| | CAB | Cabotegravir |
| | DTG | Dolutegravir |
| | EVG | Elvitegravir |
| | RAL | Raltegravir |

Comments

| DRUG.CLASS | COMMENTS |
|--------------|--|
| PI | |
| NRTI | M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication. |
| NNRTI | |
| INSTI | |